Hi All
In my ponderings whilst out for a run this morning I started to think about the imminent ending of Pfizers viagra patent in the USA in April 2020 and the possibility that taking SUD 003 onboard could extend it to 2031.
Currently viagra sales (USA only) are approx $1.14B US per annum or $12.54B total between 2020 and 2031.
Assuming that generics reduces the cost by 60% this would drop revenue by $7.524B or at a guess profit by say 50% or $3.75B over 11 years or $0.34 B per annum. ( I think this is $340M US )
Gee, to may way of thinking it makes a very compelling argument to take SUD 003 onboard asap.
I have also read that there is an agreement in place with TEVA to allow them to sell a generic in the US commencing 2017 in return for $xx royalties.
Something to think about.
kippax
-
- There are more pages in this discussion • 61 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
10.5¢ |
Change
0.005(5.00%) |
Mkt cap ! $124.8M | |||
| Open | High | Low | Value | Volume |
| 10.0¢ | 10.5¢ | 10.0¢ | $21.83K | 212.0K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 12 | 443503 | 10.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 10.5¢ | 424264 | 6 |
View Market Depth
| Last trade - 16.10pm 08/08/2025 (20 minute delay) ? |
| ALA (ASX) Chart |